Lysophospholipid receptors in drug discovery.

[1]  Bas Vroling,et al.  GPCRdb: an information system for G protein-coupled receptors , 2015, Nucleic Acids Res..

[2]  J. Aoki,et al.  Novel lysophosphoplipid receptors: their structure and function , 2014, Journal of Lipid Research.

[3]  S. Spiegel,et al.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8 , 2014, British journal of pharmacology.

[4]  Y. Fujiwara,et al.  Lysophosphatidic Acid Receptor 5 Inhibits B Cell Antigen Receptor Signaling and Antibody Response , 2014, The Journal of Immunology.

[5]  Y. Yung,et al.  LPA receptor signaling: pharmacology, physiology, and pathophysiology , 2014, Journal of Lipid Research.

[6]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[7]  B. Hemmer,et al.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview , 2014, Clinical and experimental immunology.

[8]  Todd Evans,et al.  Sphingosine 1-phosphate signalling , 2014, Development.

[9]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[10]  A. Yamashita,et al.  The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. , 2013, Prostaglandins & other lipid mediators.

[11]  Gabor Tigyi,et al.  Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression , 2013, Cancer Immunology Research.

[12]  Yasuyuki Kihara,et al.  Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy , 2013, Journal of the Neurological Sciences.

[13]  S. Higashiyama,et al.  TGFα shedding assay: an accurate and versatile method for detecting GPCR activation , 2012, Nature Methods.

[14]  J. Aoki,et al.  GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. , 2012, Journal of biochemistry.

[15]  J. Chun,et al.  Targeted Deletion of LPA5 Identifies Novel Roles for Lysophosphatidic Acid Signaling in Development of Neuropathic Pain* , 2012, The Journal of Biological Chemistry.

[16]  Sarah Spiegel,et al.  Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.

[17]  Y. Yung,et al.  Lysophosphatidic Acid Signaling May Initiate Fetal Hydrocephalus , 2011, Science Translational Medicine.

[18]  S. Milstien,et al.  The outs and the ins of sphingosine-1-phosphate in immunity , 2011, Nature Reviews Immunology.

[19]  R. Proia,et al.  The sphingosine 1-phosphate receptor S1P2 maintains germinal center B cell homeostasis and promotes niche confinement , 2011, Nature Immunology.

[20]  D. Lorrain,et al.  Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. , 2011, Arthritis and rheumatism.

[21]  M. Selman,et al.  Idiopathic pulmonary fi brosis , 2011 .

[22]  A. Bielawska,et al.  Blood sphingolipidomics in healthy humans: impact of sample collection methodology , 2010, Journal of Lipid Research.

[23]  D. Lorrain,et al.  A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model , 2010, British journal of pharmacology.

[24]  M. Akiyama,et al.  Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA‐PLA1α in autosomal recessive hypotrichosis , 2010, Human mutation.

[25]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[26]  A. Postlethwaite,et al.  A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. , 2010, Discovery medicine.

[27]  L. Carbone,et al.  Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis , 2009, International journal of medical sciences.

[28]  Takao Shimizu,et al.  Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6* , 2009, The Journal of Biological Chemistry.

[29]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[30]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[31]  M. Nöthen,et al.  G protein–coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth , 2008, Nature Genetics.

[32]  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[33]  J. Wain,et al.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.

[34]  A. Yamashita,et al.  Identification of GPR55 as a lysophosphatidylinositol receptor. , 2007, Biochemical and biophysical research communications.

[35]  K. Adachi,et al.  FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology , 2007, Perspectives in medicinal chemistry.

[36]  L. Obeid,et al.  Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  T. Hla,et al.  Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor* , 2007, Journal of Biological Chemistry.

[38]  M. Salvadori,et al.  FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[40]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[41]  A. Dubin,et al.  GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5* , 2006, Journal of Biological Chemistry.

[42]  B. Olde,et al.  Lysophosphatidic Acid Binds to and Activates GPR92, a G Protein-Coupled Receptor Highly Expressed in Gastrointestinal Lymphocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[43]  M. Ebisawa,et al.  Identification of a lysophosphatidylserine receptor on mast cells. , 2006, Biochemical and biophysical research communications.

[44]  A. Dubin,et al.  GPR 92 as a New G 12 / 13-and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP , LPA 5 * , 2006 .

[45]  Hiroshi Suzuki,et al.  LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing , 2005, Nature.

[46]  M. Pangalos,et al.  Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival , 2005, The Journal of Neuroscience.

[47]  J. Chun,et al.  Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice , 2004, Journal of Neuroimmunology.

[48]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[49]  E. Goetzl,et al.  The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  S. Payne,et al.  The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 , 2003, FEBS letters.

[51]  Takao Shimizu,et al.  Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family* , 2003, Journal of Biological Chemistry.

[52]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[53]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G-Protein-Coupled Receptors , 2002 .

[54]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[55]  J. Chun,et al.  Marked Perinatal Lethality and Cellular Signaling Deficits in Mice Null for the Two Sphingosine 1-Phosphate (S1P) Receptors, S1P2/LPB2/EDG-5 and S1P3/LPB3/EDG-3* , 2002, The Journal of Biological Chemistry.

[56]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[57]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[58]  B. Friedman,et al.  Selective Loss of Sphingosine 1-Phosphate Signaling with No Obvious Phenotypic Abnormality in Mice Lacking Its G Protein-coupled Receptor, LPB3/EDG-3* , 2001, The Journal of Biological Chemistry.

[59]  J. P. Hobson,et al.  Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. , 2000, The Journal of clinical investigation.

[60]  B. O'dowd,et al.  Characterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8* , 2000, The Journal of Biological Chemistry.

[61]  T. Yoneya,et al.  Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway. , 2000, Biochemical and biophysical research communications.

[62]  K L Napoli,et al.  The FTY720 story. , 2000, Therapeutic drug monitoring.

[63]  Hiroyuki Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid* , 1999, The Journal of Biological Chemistry.

[64]  H. Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor , EDG 7 , for Lysophosphatidic Acid * , 1999 .

[65]  E. Goetzl,et al.  Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid* , 1998, The Journal of Biological Chemistry.

[66]  C. H. Liu,et al.  Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. , 1998, Science.

[67]  S. Coughlin,et al.  Identification of cDNAs encoding two G protein‐coupled receptors for lysosphingolipids 1 , 1997, FEBS letters.

[68]  J. Weiner,et al.  Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex , 1996, The Journal of cell biology.

[69]  L. Perkins,et al.  Identification and characterization of a lysophosphatidic acid receptor. , 1994, Molecular pharmacology.

[70]  T. Hla,et al.  An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. , 1990, The Journal of biological chemistry.

[71]  Robert Altenloh.  From a Novel , 1953 .